Multimillion-dollar investment in Asturias will strengthen supply chain resilience and support growing demand for Nomex® paper across aerospace, electrical infrastructure, electric vehicle (EV), defense, and other critical markets
ALPHARETTA, Ga., Oct. 22, 2026 /PRNewswire/ -- Arclin, a leading materials science company, today announced a multimillion-dollar investment to expand floc production capacity at its Asturias, Spain facility, marking an important step in the company's strategy to invest in the long-term growth of the Nomex® business and enhance supply for customers around the globe.
Since acquiring Nomex® in April 2026, Arclin has focused on investing in capacity, reliability, and long-term growth to meet increasing customer demand. The company is delivering record paper volume in 2026 and anticipates continued supply growth in 2027.
"When we bought the Nomex® business, we committed to investing in its future," said Bradley Bolduc, Chief Executive Officer at Arclin. "Expanding production in Asturias will strengthen our global manufacturing network and help ensure we can continue supporting customers as demand grows across aerospace, electrical infrastructure, defense, and transportation markets."
The Asturias facility has been a cornerstone of the Nomex® manufacturing network since 1993. Through this investment, the site will add Nomex® paper production capabilities and become one of four production facilities in Arclin's global Nomex® paper manufacturing network. Construction is expected to be completed by the end of 2027, with full commissioning planned for early 2028.
"Our customers depend on Nomex® paper for some of the world's most demanding applications, from aircraft and electric vehicles to power generation and grid infrastructure," said Mark Glaspey, President at Arclin. "For decades, Nomex® has set the standard for performance in mission-critical applications. Building on that legacy, we are advancing the technology, developing new specifications, and working closely with customers to address evolving performance requirements and enable new applications. This investment reflects confidence in both the future of these markets and the critical role Nomex® paper plays within them."
About Arclin
Arclin is a leading materials science company and manufacturer of polymer technologies, engineered products, and specialized materials for the construction, agriculture, transportation infrastructure, weather & fire protection, pharmaceutical, nutrition, electronics, design, and other industries. Headquartered in Alpharetta, Georgia, Arclin has offices and manufacturing facilities across North & South America, Europe, and Asia and serves customers worldwide. For more information, visit www.arclin.com.
Arclin Media Contact
Jana Wright
Chief Marketing & Communications Officer
inquiries@arclin.com
Nomex® is a registered trademark of Arclin.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Arclin Announces Strategic Expansion of Nomex® Manufacturing Capacity
YICHANG, China, Oct. 23, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, has hosted the 2026 International Synthetic Biology Symposium and the Angel Group High-Quality Development Conference in Yichang, its headquarters city, on October 19–20, 2026, as part of the company's 40th anniversary celebrations.
As a highlight of Angel Yeast's 40th anniversary, the event convened over 500 global industry partners, including academicians, experts, scholars, supplier representatives, and customer delegates from China and abroad. It offered a platform to discuss biomanufacturing and synthetic biology trends, industrial innovation, and global supply chain collaboration, showcasing Angel Yeast's strategy of deepening international cooperation through innovation, openness, and localized operations.
The event was both a celebration of Angel Yeast's journey and a launchpad for global partners to deepen biomanufacturing collaboration and shape future growth together.
At the High-Quality Development Conference, Angel Yeast reflected on its journey from starting as an edible yeast pilot base to becoming the world's second-largest producer by sales volume. Today, its products reach 170+ countries and regions, serving 30,000+ customers worldwide with over 20% market share.
In innovation, Angel Yeast has built an industrial microbial strain bank and mastered key technologies in strain selection, cell factory construction and multi-carbon source fermentation. The company invests over USD 149.8 million in R&D annually, employs more than 1,500 researchers, and collaborates with over 70 research institutes worldwide.
Angel Yeast has cumulatively obtained 534 authorized invention patents, with 12 scientific and technological achievements reaching international leading levels. The company has continuously optimized its market layout and refined a research-and-sales synergy mechanism adapted to its new development stage composing of 4 business segments, 6 overseas business divisions and 8 technology centers.
Globally, Angel Yeast operates a multi-regional production and R&D network. Its Egypt plant, after two expansions, is now the world's largest yeast factory, while its new Indonesia plant is set to begin production in Q1 next year. Overseas factories and subsidiaries employ nearly 2,000 foreign staff, with a localization rate exceeding 95%.
Angel Yeast is committed to a circular economy industrial chain: raw materials sourced from agricultural processing, core products serving food health and safety, and by-products feeding back into agriculture. It has built five National Green Factories and one zero-carbon factory, with its Ecovadis rating in the global top 15%. The company also participates in setting international standards, including the Codex Alimentarius standard for yeast products, driving the coordinated global expansion of its products, technologies, standards, and brand.
"Looking ahead, Angel Yeast will vigorously develop new synthetic biology technologies, focusing on new tracks such as future foods, biomedicine, enzyme catalysis and new materials, and agricultural microbiology. We will build a 'biomanufacturing+' industrial cluster, continuously propel the industrial chain toward the high end of the value chain, and strive to build a world-class biotechnology company," remarked Xiong Tao, Chairman of Angel Yeast.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Angel Yeast Marks 40th Anniversary, Setting Its Sights on Becoming a Global Biotech Powerhouse
